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Original Article
ACQUIRED APLASTIC ANEMIA:
TREATMENT IN A DEVELOPING COUNTRY
Shaheena Hanif1, Farah Naz2, Emad uddin Siddiqui3, Jamal Raza4
ABSTRACT
Objective: The aim of this study was to evaluate the clinical presentation of aplastic anemia as
well as to assess the efficacy of Cyclosporin -A in patients with aplastic anemia.
Methodology:  This is a hospital based interventional study. During the three year study period,
44 children were enrolled. Mean age was 9.3 years and there was a male predominance.
Results: Most common clinical presentation was anemia and bleeding. Four children died before
therapy was started. Cyclosporin-A was started in 40 patients. Eleven patients died before
completion of therapy and three patients were lost to follow-up. Out of 26 patients who
completed therapy, 11 were cured and 9 were responders while 6 were non responders according
to the selected criteria.
Conclusion: In developing third world countries like Pakistan majority of the patients with
aplastic anemia cannot afford BMT. Alternative modalities of treatment must therefore be looked
into. Cyclosporin-A seems to be a reasonable therapeutic option in such cases.
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INTRODUCTION
Severe aplastic anemia is a syndrome char-
acterized by bone marrow failure with periph-
eral cytopenia and a hypocellular bone mar-
row biopsy, without blasts or myelodysplasia.1
It primarily affects children, young adults, and
those over 60 years of age. The majority of cases
are idiopathic; however, idiosyncratic reactions
to some drugs, chemicals, and viruses have
been implicated in its etiology. Probably an
autoimmune T-cell reaction causes the stem
cell depletion, but the precise mechanism, as
well as the eliciting target antigens, is
unknown. Symptoms vary from severe life-
threatening cytopenias to moderate or non-
severe disease that does not require transfu-
sion support.2
The treatment of first choice for these patients
is allogeneic bone marrow transplantation
(BMT) from a sibling matched for HLA-A,
HLA-B and HLA-DR. BMT is limited by treat-
ment related toxicity and by availability of
matched donors. Unfortunately only 30% of
patients have an HLA-matched sibling (25%
chance per sibling). Immunosuppression is an
alternative to BMT i.e. Antithymocyte globu-
lin (ATG) and cyclosporine.1,3 ATG unfortu-
nately is also an expensive option, beyond the
reach of many of our local patients. The miser-
ies of these patients and their parents are fur-
ther increased by difficulty in getting blood and
blood products.
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However, immunosuppression is only a
bridging therapy. About a third of patients fail
to respond, and even responders may have
chronically low blood cell counts. These prob-
lems have resulted in remarks like immunosup-
pression only “postpones the inevitable.” The
present study was conducted to evaluate the
clinical presentation of Acquired Aplastic Ane-
mia and to assess the efficacy of cyclosporin-A
along with steroids, in patients with aplastic
anemia who cannot afford other treatment
options of  immunosuppressive therapy with
antithymocyte globulin.
Since the early 1980s Cyclosporin-A has been
used in the management of patients with
aplastic anemia who cannot undergo BMT.
Cyclosporin A is a potent immunosuppressive
agent, cheap, easily available and less toxic. It
has marked immunosuppressive effects and
lacks myelotoxicity and is therefore used to
treat a range of inflammatory and immune
mediated diseases. The mechanism of action is
complex. It affects the early phase of T cell ac-
tivation and inhibits lymphokine production.
It has little inhibitory effects on B cell function.
It can be used alone or in combination with
methyl prednisolone or along with
antithymocytic globulin.5,6
Although ATG has been used extensively, the
exact mechanism of its action is still not well
understood.7 The reported response rate from
ATG ranges from 30% to 75%. Combination
of ATG and cyclosporin-A along with granu-
locytes colony stimulating factor (G-CSF)
improves the response rate up to 70- 80%.8
ATG is also not free of side effects and is
expensive and so Cyclosporin-A alone can also
be used as a valuable therapeutic option for
the treatment of aplastic anemia.
PATEINTS AND METHODS
The study was conducted from June 2000 to
May 2003 at The National Institute of Child
Health, Karachi. All children presenting with
pallor, petechiae, bruises and mucosal bleeds
with clinical suspicion of bone marrow failure
were enrolled. Patients with obvious
dysmorphic features suggestive of Constitu-
tional Aplastic Anemia, laboratory evidence of
leukemia, myelodysplasia and lymphoma were
excluded. Hemoglobin, total and differential
leucocytes counts, platelets, reticulocyte count,
red cell indices and peripheral smear were
done in all patients. Confirmation of diagnosis
of aplastic anemia was based on bone marrow
aspirate and or trephine biopsy. Renal, liver
function and screening for hepatitis B & C was
undertaken in every patient before starting
therapy. Hams test was done to exclude
nocturnal hemoglobinuria.
Chromosomal breakage studies were carried
out in all those, consistent with Fanconi were
excluded from the treatment protocol. The
patients were classified according to the sever-
ity based on Cammitta classification.9,10
Based on the selected criteria, 44 patients
were enrolled during the three year study
period.
The children were started on steroids and
cyclosporin-A. Intravenous methylpredniso-
lone was given from day 1-5, followed by oral
steroid to complete two weeks of steroid
therapy. Oral cyclosporin-A was started from
the first day and continued for 18-24 months.
Treatment Protocol:
* Injection methyl prednisone 2mg/kg/day
from day 1 to 5.
* Tablet prednisone 1mg/kg/day from day 6
to 14.
* Tablet cyclosporin-A 10mg/kg/day from
day 1 onwards.
The duration of cyclosporin-A therapy was
determined by the time required to achieve
transfusion independence. Therapy was given
for 18 months to those patients who achieved
transfusion independence within one year of
starting therapy. Treatment was given for 24
months to patients who achieved transfusion
independence after 12 months of starting
cyclosporin therapy. Patients were followed at
monthly intervals in the out- patient clinic.
Assessment of response to therapy was made
by regular measurements of hemoglobin, total
leucocytes, neutrophils and platelets counts.
Record of blood and blood product transfusion,
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infective and hemorrhagic complications was
maintained. Patients were also monitored for
side-effects of cyclosporin therapy.
Measurement of outcome:8
Cured: Achievement of transfusion indepen-
dence and maintains of hematological response
at the completion of cyclosporin therapy.
Responders: Transfusion independence while
on cyclosporin therapy and an absolute neu-
trophil count of > 1500 mm,3 platelet count
>150000/ml and hemoglobin > 11gm%.
Non- Responders: No hematological response
after 6 months of commencement of
cyclosporin therapy.
Relapse: A drop in platelet count to < 20000/
ml, hemoglobin <8gm% and absolute neutro-
phil count < 1000 mm,3 after an initial response
of at least 2 months.
RESULTS
During the three year study period, 44
children were enrolled in the study. The age of
the patients ranged from 2.5 to 13 years. The
male to female ratio was 3.4:1. The age range
and clinical signs at admission are shown in
Figure-1, Table-I.
According to Cammitta classification 4
patients had very severe aplastic anemia
(VSAA), 12 patients had severe aplastic ane-
mia (SAA) and 28 patients were diagnosed as
having non severe aplastic anemia (NSAA).
Four patients died before the treatment was
started. Two died of severe neutropenia and
sepsis and the other two died of intracranial
bleeding. Forty patients were started on
cyclosporin therapy, out of which 11 expired
during the course of the treatment 6(54%) due
to intracranial hemorrhage, 4(36.6%) died be-
cause of septicemia and 1(9%) was unluckily
expired because of renal failure. Three patients
lost the follow up. The fate of patients on treat-
ment is described in Table-II
Cyclosporine therapy was continued in the
26 surviving patients. Majority of these had
NSAA. The transfusion of blood and blood
products decreased in patients on therapy
Figure-2. Out of the 26 patients, 11 (42.3%)
were completely cured and 9 (34.6%) were still
on treatment at the end of the study and
showed significant improvement in the counts
of all three cell lines while 6 (23.0%) were non
responders.
DISCUSSION
In the past 30 years morbidity and mortality
from aplastic anemia has decreased dramati-
Emad uddin Siddiqui et al.
Table-I: Clinical sign at Presentation
Sign No. of Patients
Anemia 33
Petechiae/Purpura 39
Ecchymoses 4
Mouth Ulcers 4
Fig-1: Age groups of patients presenting with
Aplastic anemia.
Table-II: Fate of patients started on
Cyclosporin therapy.
Response No. of Patients
     (n=40)
Cured (off Treatment) 11
Responder (On Treatment) 9
Non Responder 6
Expired before 11
  completion of therapy
Lost to follow up 3
Expired before the start 4
  of therapy 
Total 40
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cally, primarily because of effective treatment
modalities like BMT, stem cell transplantation
and immunosuppression with ATG. Five years
survival rates are now 70% to 90%.11 Patients
not fulfilling the criteria for BMT or those un-
able to afford treatment with one of the more
expensive immunosuppressant need an alter-
native option. Multiple immunosuppressive
regimens have been tried in this regard with
variable success rates. Cyclosporin- A is an
easily available and cheap immunosuppress-
ing agent that can be used in an out patient
setting, further cutting down the cost of
hospital stay.
In the present study cyclosporin-A along
with steroids was used in the treatment of ac-
quired aplastic anemia. Majority of the patients
in the current study were male. Most studies
conducted in the past have reported a similar
pattern.12,13 Some have documented female pre-
ponderance.14 Age range of the patients in the
present study was 2.5 to 13 years with a mean
of 9.3 years, which is similar to that reported
in the other studies.15,16
Majority of the children in the current study
presented with anemia and hemorrhages,
mostly in the form of skin bleeds. This mode of
presentation of the disease is the same as com-
pared to other studies.13,14 Out of 26 patients
who completed therapy, 42.3% were cured and
34.6% were responders and 23% were non
responder according to the selected criteria.
Similar cure rates have been documented by
Rai, in a study conducted at Banaras.17 In the
past cyclosporin monotherapy has been used
with variable success rates of between
16%-85%, depending upon the severity of the
disease, with a better response observed in
patients with NSAA.8 A recent study done by
Agha has shown significant response rates in
patients of acquired aplastic anemia treated
with cyclosporin-A and steroids.13 Another
large French multicenter trial attempted a
direct comparison of cyclosporin versus ATG
as initial treatment for aplastic anemia and
found no difference in the outcome.18 Some of
the more recent studies have used a more
intensive regimen of Cyclosporin- A along with
steroids and G-CSF with a response rate of
between 45-70%.19  In the present study
cyclosporin-A was used in a dose of 10mg/
kg/day, which is the recommended protocol
in many studies.18,20
Transfusion requirement of patients on
cyclosporin-A therapy decreased markedly.
Eleven patients died in the first 6 months of
starting therapy mostly due to infection and
hemorrhages. One patient died as a side effect
of therapy. Response could not be evaluated
in these patients. The most common side effect
of cyclosporin-A noted in patients was hirsut-
ism, which was observed in 29 patients. One
patient developed renal failure and expired
during the course of the therapy. Three had
deranged LFTs and recovered within two
weeks, on decreasing the dose of cyclosporin.
Nephrotoxicity was the most common side
effect observed in a large trial of 66 children
treated with cyclosporin-A.8 Others have
found liver toxicity to be the most
common.18,19 But in general cyclosporin-A is a
well-tolerated immunosuppressive agent for
the treatment of aplastic anemia. Compared
to ATG it is safer as it is less toxic and less im-
munosuppressive and thus carries a lesser
chance of early death due to infection.8,18
Untreated Aplastic anemia has a very high
mortality rate, and cyclosporin-A appears to
be a reasonable therapeutic option for patients
Aplastic Anemia
Fig-2: Transfusion requirement of patients on
cyclosporin therapy.
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who cannot undergo BMT due to non-identi-
cal donor or cost constraints. It can help in
achieving remission in 40% of patients, while
in the remaining patients it can slow down the
stormy course of the disease, maintain the
peripheral blood counts and reduce the
transfusion requirements.
CONCLUSION
The decision of management of aplastic
anemia in a developing country like ours is
largely limited by the availability of resources.
Although allogenic BMT from a HLA matched
sibling is the treatment of choice but
cyclosporin-A along with steroids is a reason-
able alternative.
REFERNCES
1. Hernandez-Rivera EG. Hematopoietic stem-cell trans-
plantation in aplastic anemia. Rev Invest Clini
2005;57(2):298-304.
2. Keohane EM. Acquired aplastic anemia. Clin Lab Sci
2004;17(3):165-71.
3. Moore MA, Castro-Malaspina H. Immunosuppres-
sion in aplastic anemia: Postponing the inevitable? N
Eng J Med 1991;324:1358-60.
4. Leeksma OC, Thomas LLM, Vander Leslle J. Effec-
tiveness of low dose cyclosporin in acquired aplastic
anemia with severe neutropenia. Meth J Med
1992;41:143-49.
5. Tichelli A, Schrezenmeier H, Bacigalupo A. Immuno-
suppressive treatment of aplastic anemia:
Schrezenmeier H, Bacigalupo A., editors. Aplastic
anemia: Pathophysiology and treatment. Cambridge
UK: Cambridge University press, 2000;154-96.
6. Guinan EC. Clinical aspects of aplastic anemia. Hem-
atol-Oncol Clinics of North Am 1997;11(6):1025-44.
7. Maschan A, Bogatchena N, Kryjanovsll O, Shneider
M, Litvinov D, Mitiushkina T, et al. Results at a single
center of immunosuppression with cyclosporin-A in
66 children with aplastic anemia. Br J Haematol
1999;106:967-70.
374  Pak J Med Sci   2007   Vol. 23   No. 3     www.pjms.com.pk
Emad uddin Siddiqui et al.
8. Alter BP, Potter NU, Li FP. Classification of Aplastic
anemia. Clinical Hematol 1076;7:431-65.
9. Sujita K. Therapeutic approaches to childhood ac-
quired aplastic anemia. Current Opinion in Investig
Drugs 2001;2(2):237-43.
10. Abkowits JL. Aplastic anemia: Which treatment? Ann
of Int Med 2001;135(7):524-6.
11. Supelveda E, Brethauer U, Rojas J, LeFort P. Oral mani-
festations of aplastic anemia in children. J Am Dent
Assoc 2006;137(4):474-8.
12. Ali AS, Hamid MH, Khan MA, Ahmed FN. Acquired
Aplastic Anemia – an experience with different drug
therapies. Pak Paediat J 2003;27(1):19-27.
13. Field SR, Follmann D, Nunez O, Neal S, Young MD.
ATG and Cyclosporin –A for severe aplastic anemia.
JAMA 2003;289(9):1130-35.
14. Clausen N, Kreuger A, Salmi T, Storm Mathisen I,
Johannesson G. Severe Aplastic Anemia in Nordic
Countries: A population based study of incidence,
presentation, course and outcome. Archives Dis
Childhood 1996;74:319-22.
15. Bessho F, Imashukus, Hibi S, Tsuchida M, Nakahata
T, Miyazaki S, Kojima S, et al. Serial morphologic
observation of bone marrow in aplastic anemia in
children. Int J Hematol 2005;81(5):400-4.
16. Rai M, Singh VP, Shukla J, Sundar S, Jha VC. Low
dose cyclosporin- A therapy in severe Aplastic ane-
mia. J Assoc Physicians Ind 2001;49:966-9.
17. Gluckman EH, Esperou-Bourdeau A Baruchef M,
Boogaerts J, Briere Donadio D, et al. Multicentre ran-
domized study comparing cyclosporin – A alone and
ATG with prednisone for the treatment of aplastic
anemia. Blood 1992;79(10):2540-46.
18. Fuhrer M, Rampf U, Baumann I, Faldun A, Niemeyerc,
Janaka-Schaub G, et al. Immunosuppressive therapy
for aplastic anemia in children: a more severe disease
predicts better survival. Blood 2005;15(6):2102-4.
19. Frickhofen N, Kartwassa JP, Schrezenmeir H. Treat-
ment of Aplastic Anemia with anti-thymocyte globu-
lin and Methyl Prednisone with or without
Cyclosporin. N Engl J Med 1991;324:1297-1304.
